TempraMed’s VIVI Cap 1 Can Change the Way People Who Inject Insulin Live their Lives

TempraMed is creating easy to use, hassle free solutions that save patients lives by protecting them from damaged medications. TempraMed’s products provide the last mile control management for injectable and temperature sensitive pharmaceuticals, helping patients to manage and control their medications, enabling them to live safer and more spontaneous lives.

TempraMed’s recently launched VIVI Cap 1 is an easy-to-use reusable insulin pen cap that keeps diabetes insulin at a safe temperature 24/7 365 days a year, for years on end without need for any user intervention. The product is FDA registered and CE marked.

Insulin is a protein that spoils and degrades in the wrong temperature conditions. From the point of manufacturing up until it is used, insulin needs to be kept between 36° to 46°F. During use, insulin does not have to be refrigerated but it should stay below 86°F and should not freeze. Insulin must be protected from such exposure.

Injecting insulin that has broken down due to time or temperature, results in poor blood sugar control, and in time can lead to increased dosages and sometimes hospitalization for stabilization.

The VIVI Cap 1 shields insulin in-use from potential temperature damage. Thus, reducing the risk of using damaged insulin and wasting money from discarded insulin that might have been compromised.

Mr. Ron Nagar, TempraMed CEO and Founder, stated “After spending years recognizing the endless struggle that people with diabetes have to gain control over blood glucose levels, I noticed that those on insulin, take it for granted that insulin is always the same and at its best. But sadly, that is not the reality, so in order to protect the insulin without adding any hassle we developed this unique device and made it available for all.”

VIVI Cap uses a unique patented combination of special insulation with “self-regenerating” heat absorbing material and control electronics, this enables the device to operate for years without requiring any user attention or handling. There are no power requirements, no charging and no preliminary preparations needed. For people spending their working days outdoors, there has not been an alternative hassle-free solution that can be used every day to protect insulin from spoiling.

 

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.